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Abstract 28 
There is a need for improved understanding of how different cerebrovascular reactivity (CVR) 29 
protocols affect vascular cross-sectional area (CSA) when measures of vascular CSA are not 30 
feasible. In human participants, we delivered ~±4mmHg end-tidal partial pressure of CO2 31 
(PETCO2) relative to baseline through controlled delivery, and measured changes in middle 32 
cerebral artery (MCA) cross-sectional area (CSA; magnetic resonance imaging (7 Tesla MRI)), 33 
blood velocity (transcranial Doppler and Phase contrast MRI), and calculated CVR based on 34 
steady-state versus a ramp protocol during two protocols: a 3-minute steady-state (+4mmHg 35 
PETCO2) and a ramp (delta of -3 to +4mmHg of PETCO2). We observed that 1) the MCA did not 36 
dilate during the ramp protocol, but did dilate during steady-state hypercapnia, and 2) MCA blood 37 
velocity CVR was similar between ramp and steady-state hypercapnia protocols, although 38 
calculated MCA blood flow CVR was greater during steady-state hypercapnia than during ramp, 39 
the discrepancy due to MCA CSA changes during steady-state hypercapnia. Due to the ability to 40 
achieve similar levels of MCA blood velocity CVR as steady-state hypercapnia, the lack of change 41 
in MCA cross-sectional area, and the minimal expected change in blood pressure, we propose that 42 
a ramp model, across a delta of ~-3 to +4mmHg PETCO2, may provide one alternative approach 43 
to collecting CVR measures in young adults with TCD when CSA measures are not feasible.      44 
 45 
Keywords 46 
cerebrovascular reactivity, hypercapnia protocols, transcranial Doppler, magnetic resonance 47 
imaging, middle cerebral artery dilation 48 
 49 
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 Introduction 52 
Cerebrovascular reactivity (CVR) studies assess changes in cerebral blood flow to a known 53 
vasoreactive stimulus (e.g., changes in end-tidal partial pressure of CO2; PETCO2). Measures of 54 
CVR are important because attenuated CVR may reflect preclinical vascular pathophysiology and 55 
an increased risk of mortality independent from cardiovascular risk factors or stroke incidence (1). 56 
The most commonly used technique for CVR measures in humans, transcranial Doppler (TCD) 57 
ultrasonography, provides an index of vascular blood flow changes (i.e., blood velocity) because 58 
the vascular cross-sectional area (CSA) values required for blood flow calculations (i.e., the 59 
product of CSA and blood velocity) are not collected with TCD. Thus, an assumption of an 60 
unchanging CSA is typically accepted, raising concern if changes in CSA do occur (2). To 61 
circumvent issues related to TCD measures of CVR, some research groups measure all four brain-62 
supply (i.e., carotid and vertebral) arteries outside of the brain (3), or use expensive neuroimaging 63 
approaches (4,5).  64 
An additional concern regarding quantification of CVR is the potential for changes in central 65 
hemodynamics during hypercapnia  (elevated PETCO2) that could elevate cerebral blood flow due 66 
to changes in cardiac output (6) and blood pressure (6,7) and not directly due to cerebrovascular 67 
dilation (7). Another complicating factor in quantifying CVR between groups is potential variation 68 
in large cerebral artery reactivity, particularly when comparing age differences (8). As an example, 69 
our group’s previous work showed that compared to younger adults, older adults exhibited 70 
attenuated changes in large cerebral artery CSA in response to steady-state hypercapnia (9). 71 
However, obtaining cerebral artery CSA data requires access to costly MRI or CT systems. We 72 
aim to understand protocol designs that provide accurate CVR estimates when using TCD 73 
methods. The “ideal” velocity based CVR protocols conducted using TCD would require: 1) 74 
minimal CSA changes by conducting CVR protocols that result in negligible change in CSA, and 75 
2) minimal influence of confounding variables such as blood pressure.  76 
In the current study, we tested the hypothesis that a ramp (i.e., linear) CVR protocol within the ±5 77 
mmHg range of relative changes in PETCO2 would provide minimal changes in CSA while still 78 
replicating CVR outcomes from the more standard steady-state hypercapnia CVR protocol. Our 79 
rationale for this range of relative changes in PETCO2 comes from the emerging knowledge of a 80 
sigmoidal change in MCA CSA, with minimal changes in hypercapnia, within the -5 to +5 mmHg 81 
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from resting PETCO2 (10). We chose a ramp-style CVR protocol to compare to CVR measures 82 
from a steady-state hypercapnia protocol (0 to ~5 mmHg) because: 1) the ramp protocol is a well-83 
established protocol for CVR measures (7,11,12), and 2) existing means for calculating CVR from 84 
standard steady-state protocols use linear slope methods which simply reduce to a ramp design. 85 
We acknowledge that the ramp protocol within the ~∆±5 mmHg from baseline PETCO2 range may 86 
potentially affect vascular dilation differently than a steady-state hypercapnia protocol as the 87 
hypocapnia portion preceding hypercapnia may blunt blood velocity CVR (13). A sub-analysis in 88 
our earlier work, however, indicated that order of condition did not affect CSA reactivity in young 89 
adults (4). Additionally, existing methods primarily focus on velocity-based CVR without 90 
considering CSA, and we wanted to design a CVR protocol that minimized CSA changes (even if 91 
it involved hypocapnia) and blood pressure changes while retaining its ability to elevate cerebral 92 
blood flow (i.e., changing blood velocity). Other models can be considered but we want to test the 93 
ramp protocol as one example of alternative CVR designs that may elicit negligible CSA and BP 94 
changes when measuring blood velocity CVR using TCD. 95 
To achieve the high temporal resolution of the MCA CSA for the required study, we developed a 96 
dynamic anatomical imaging sequence with high-temporal and spatial resolution to capture MCA 97 
CSA changes every 14 seconds throughout each vasoreactivity protocol (~±∆4 mmHg) using 7T 98 
magnetic resonance imaging. Our objectives were to assess whether between steady-state and ramp 99 
protocols: 1) the MCA CSA increased compared to baseline, 2) blood pressure remained stable 100 
throughout duration of the protocol, and 3) MCA blood velocity (via TCD alone), and calculated 101 
flow vasoreactivity were similar. 102 
Materials and Methods 103 
Participants 104 
All testing was conducted at the Centre for Functional and Metabolic Mapping at The University 105 
of Western Ontario. The Human Subjects Research Ethics Board at the University of Western 106 
Ontario (London, Ontario, Canada) approved the experiment protocols herein. Informed consent 107 
from 12 healthy subjects (19-25 years of age; 6 males) was obtained prior to scanning. A sample 108 
size calculation was based off of our previous work with blood velocity reactivity measured with 109 
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TCD during steady-state hypercapnia (4). Specifically, for a within-subject design, with a Cohen’s 110 
d of 1.02, alpha level of significance of 0.05, and statistical power of 0.80, we calculated a sample 111 
size of 10 and recruited 12 individuals due to our laboratory’s expected attrition rate of 10-12% 112 
with our neuroimaging studies. Participants were ineligible if they were smokers, pregnant, or had 113 
any of the following conditions: Raynaud’s disease, respiratory illnesses, diabetes, claustrophobia, 114 
history of psychosis, eating disorders, manic or bipolar disorder, major psychiatric conditions, or 115 
dependence on alcohol or drugs.  116 
Procedure and data recording 117 
Testing was completed between 10am – 2pm. Participants refrained from exercise, alcohol, drugs, 118 
and caffeine within 12 hours prior to testing. We used TCD and MRI to assess the cerebral 119 
vasoreactivity in response to steady-state (three minutes) bouts of hypercapnia (HC), and a ramp 120 

















Figure 1 – Experimental protocol schematic. Left: Experimental setup displaying real-time data 
collection for both transcranial Doppler and MRI sessions. Right, panel a: Ramp hypercapnia protocol 
with a desired target range of -5 to +5 mmHg from baseline PETCO2 and a duration of 240 seconds. 
Right, panel b: Steady-state hypercapnia (SSHC) protocol with a target range of +5 mmHg from baseline 
PETCO2 and a duration of 180 seconds. Protocols were executed using the RespirAct™ device with 
preset protocols programmed with the desired PETCO2 values. 
 
Steady-state and ramp protocols were each conducted twice, once for each of the TCD and MRI 122 
portions of the testing sessions and the order of TCD and MRI trials was randomized across 123 
participants. Unfortunately, we were unable to randomize the order of CVR protocols as it was 124 
difficult to stop and restart the RespirAct™ (Thornhill Research Inc., Toronto, Ontario, Canada) 125 
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without doing extensive recalibration. The desired ventilatory rate was set to 12 breaths/min using 126 
a visual metronome for each session and was projected on a screen during the MRI scan. Our goal 127 
was to have the protocols fall within the ±5 mmHg from baseline PETCO2 range. Following a 128 
familiarization period of four minutes, the order and duration of protocols occurred as follows: 1) 129 
baseline (1 minute), 2) steady-state hypercapnia (target was +5 mmHg, although only reached 130 
~+4mmHg; three minutes), 3) recovery (2 minutes) 4) baseline (1 minute), 5) -5 mmHg PETCO2 131 
hypocapnia (brief hyperventilation; target was +5mmHg, although only reached ~ -3mmHg) 30 132 
seconds), 6) incremental increase (ramp) from ~ -3 mmHg hypocapnia to ~ +4 mmHg relative 133 
PETCO2 hypercapnia (four minutes), 7) recovery (two minutes).  134 
Manipulating target PETCO2 stimulus 135 
Prior to the MRI scan, participants were fitted with a facemask attached to the RespirAct™ system, 136 
a modified sequential gas delivery breathing circuit(13) was used to clamp PETCO2 levels at the 137 
desired +5 or -5 mmHg (depending on protocol). Breathing rate and tidal volumes were calibrated 138 
prior to starting the breathing sequence.   139 
MCA blood velocity and systemic blood pressure 140 
 While supine, continuous beat-to-beat arterial blood pressure was monitored using a Finapres® 141 
Finometer system, where a finger cuff was placed on the middle phalange of the third finger, and 142 
the finger blood pressure was calibrated with an upper arm cuff (Finapres® Medical Systems, 143 
Amsterdam, Netherlands). The MCA was insonated with a 2 MHz ultrasound probe placed at the 144 
temporal window and the peak blood flow velocity envelope was collected using the Neurovision 145 
TCD System (Multigon Industries Inc., NY, USA). All analog data were sampled at 1000 Hz using 146 
the PowerLab data acquisition system (ADInstruments, Dunedin, Otago, New Zealand).   147 
MCA vascular diameter and blood velocity during MRI 148 
 A 7 Tesla MRI (Siemens, Magnetom Step 2.3, Erlangen, Germany) system was used to acquire 149 
the following datasets: 1) 3D time-of-flight (TOF) with 0.8mm isotropic voxel resolution, echo 150 
time (TE)/ repetition time (TR) = 2.59ms/18ms, flip angle (FA) = 15⁰, bandwidth (BW) = 151 
203Hz/pxl; 2) single-slice 2D phase contrast (PC-MRI) for MCA M1 segment blood velocity, with 152 
a voxel resolution of 0.3×0.3×1.4mm3, TE/TR = 7.72ms/24.3ms, four averages, FA = 20⁰, 153 
velocity-encoding (Venc) = 100cm/s and BW = 250Hz/pxl. During PC-MRI, a Venc value of 154 
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100cm/s was used for all subjects, except for one hypercapnic case, where a Venc of 130cm/s was 155 
used to avoid wrap-around artifact; and 3) cross-sectional area of the MCA M1 segment using 156 
single-slice 2D turbo spin-echo T1-weighted imaging with 0.5×0.5×1.5 mm3, TE/TR = 12/750ms, 157 
BW = 270Hz/pxl, with an acquisition time of 13-14 seconds. The TOF data were used to locate a 158 
straight segment on the right MCA M1 segment with the least curvature. The single-slice PC-MRI 159 
and T1-weighted data were then acquired orthogonally to the axis of the selected MCA segment. 160 
The T1-weighted data were acquired sequentially in order to monitor the changes in MCA 161 
diameter.  162 
Data analysis 163 
Data analysis was carried out offline using custom R scripts (RStudio; v. 2020), GraphPad (V.8), 164 
and LabChart Pro (v.8, ADInstruments, Dunedin, Otago, New Zealand). 165 
Transcranial Doppler ultrasound 166 
The MCA blood velocity (via TCD) and MAP were averaged beat-by-beat over the cardiac cycle 167 
then were exported at 5 Hz sampling frequency and saved as text files (LabChart Pro v.8, 168 
ADInstruments, Dunedin, Otago, New Zealand). During the TCD collection phase of testing, start 169 
and end times of each event throughout the experimental breathing protocol were chronicled by 170 
comments added in the LabChart file.  171 
Magnetic resonance imaging (MRI; 7 Tesla) 172 
During the MRI collection phase of testing, start and end times of each event were chronicled 173 
based on the time associated with the desired PETCO2 on the exported RespirAct™ data file. For 174 
the T1-weighted anatomical MCA images, start and end times for each protocol event were 175 
recorded based off the MRI console such that images were lined up offline based on the DICOM 176 
image acquisition time. The brain anatomical images were imported into a DICOM reader, OsiriX 177 
software (Pixmeo©, Bernex, Switzerland), and MCA cross-sectional area (CSA) was measured by 178 
a blinded rater (MK) and compared against an expert rater (BKA).  179 
The PC-MRI data were acquired for 30 seconds at baseline and within a ~70-second window 180 
following 50-60 seconds from the start of steady-state hypercapnia (as noted on Fig 4, panel J with 181 
the PC-MRI text bar). The MCA blood velocity measurements during the MRI session were 182 
obtained from PC-MRI data by manually contouring a region-of-interest (ROI) inside the MCA 183 
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lumen. The contours were drawn using the software, signal processing in NMR (SPIN-Research, 184 
MR Innovations Inc., Detroit, MI, USA). Care was taken to avoid any peripheral voxels within the 185 
MCA lumen. The magnitude PC-MRI data was used to locate the MCA lumen. The peak velocities 186 
were calculated for each subject for baseline and hypercapnic states.  187 
Data extraction 188 
The LabChart text files, the TCD and MRI session RespirAct™ breath-by-breath PETCO2 values, 189 
and the measured CSA were aligned using RStudio (v. 2020) (14) for data extraction from specific 190 
epochs as indicated by the event comments in each file. The “print” function in the “magicfor” 191 
package in R (15) was used to extract data with each loop iteration for each participant, and 192 
variables of interest were exported as .csv files and imported to GraphPad Prism for graphing and 193 
analysis.  194 
Steady-state condition time courses were baseline corrected by subtracting mean baseline value (-195 
30 to 0 seconds of time window of interest) for each respective variable and plotted as delta values 196 
(Fig. 4). For the baselines and steady-state condition, the data were extracted from the following 197 
sections within the protocol: 1) 30 seconds baseline prior to onset of hypocapnia prior to the ramp 198 
protocol and 2) 30 seconds baseline prior to steady-state hypercapnia, and 3) 60 seconds at the end 199 
of steady-state hypercapnia. The ramp slope analysis included the entire hypocapnic to 200 
hypercapnic incremental data (see below).  201 
Ramp protocol 202 
The target PETCO2 and ramp protocol schematic is shown in Fig. 1, panel a. The target ventilation 203 
rate was 12 breaths/minute and participants were coached using a visual metronome. In order to 204 
equalize the spacing on the time axis when plotting the achieved PETCO2 data, the PETCO2 and 205 
corresponding time vectors were resampled to a fixed 12 breaths/minute sampling rate using the 206 
base R “approx” function in RStudio. Thus, two time vectors were created: 1) a target time vector 207 
that is based off of a 12 breath/minute ventilation rate and 2) a “fixed” time vector that is based 208 
off of resampling each participants data to meet the target time vector. The inter-individual 209 
differences for the “fixed” time vector are indicated by horizontal error bars (mean ± S.D.; Fig. 3, 210 
panels a-b), and the data are plotted and averaged for all participants along the target 12 211 
breaths/minute time vector.  212 
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MCA blood velocity and systemic MAP data (in 0.2 second increments or 5 MHz sampling 213 
frequency) were plotted from the hypocapnic state to the hypercapnic state during the ramp 214 
protocol and averaged at each time point across the 12 participants (Fig. 3 panels c-d). Similarly, 215 
the CSA values along the ramp protocol were averaged for each time point across participants 216 
(Fig. 3 panel e). Although our goal was to collect 4 minutes of ramp data, the transition point from 217 
the nadir of hypocapnia to start of ramp was different for each person and it generally took 218 
approximately 2 breaths (~12 seconds) to sync with the desired PETCO2 for the hypercapnic ramp. 219 
Thus, to ensure the same number of samples (n=12) for each time point along the ramp protocol, 220 
we only extracted the last 228 seconds of ramp data for all participants (instead of the full 240 221 
seconds).  222 
Steady-state protocol 223 
Data extraction and organization were similar to the ramp protocol except data extraction occurred 224 
between the start and end of the three-minute steady-state hypercapnia stimulus. As previously 225 
mentioned, the PC-MRI data acquisition commenced 50-60 seconds from start of steady-state 226 
hypercapnia. Thus, the continuous T1-anatomical MCA CSA scans were interrupted to allow for 227 
PC-MRI imaging (correlation with TCD measures of blood velocity are shown in Fig. 2). PC-MRI 228 
data were collected for 11 out of our 12 participants. As there were shifts in PC-MRI data collection 229 
start and end times across participants, the upper and lower bounds of these time points are 230 
indicated under the “PC-MRI” text bar on Fig. 3 (panel e, bottom row) to indicate to the reader 231 
that the mean and S.D. for CSA values in this portion of the protocol do not include all 11 232 
participants (i.e., n < 11) for the CSA data. 233 
The averaged raw values for the 30 seconds baseline (prior to start of stead-state hypercapnia; 234 
indicated as B on x-axis in Fig. 4) and last minute of steady-state hypercapnia (indicated as SSHC 235 
on x-axis on Fig. 4) are shown in Fig. 4 for PETCO2, MCA blood velocity (via TCD) and mean 236 
arterial pressure (MAP) during the TCD session and the PETCO2, MCA blood velocity (via PC-237 
MRI) and MCA CSA during the MRI session. 238 
MCA blood velocity reactivity calculations 239 
The ramp and steady-state hypercapnia MCA blood velocity cerebrovascular reactivity (CVR) 240 
measures are shown in Fig. 5 panel a. For the ramp protocol, the MCA blood velocity slope (Fig. 241 
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3 panel c) and the PETCO2 (for TCD session; Fig. 3 panel a) slope were calculated for each person 242 
and the MCA blood velocity CVR was calculated as:  243 
MCA Blood Velocity CVR	=	MCA Blood Velocity Slope
PETCO2 Slope
      (1) 244 
For the steady-state hypercapnia protocol, the difference between the average baseline before start 245 
of hypercapnia and the average of the last minute of hypercapnia (i.e., the difference between the 246 
SSHC and B conditions in Fig. 4) were calculated. For each individual, the MCA blood velocity 247 
CVR during the steady-state hypercapnia condition was then calculated as: 248 
MCA Blood Velocity CVR	=	 ∆MCA Blood Velocity
∆PETCO2
   (2) 249 
MCA blood flow reactivity calculations 250 
The ramp and steady-state hypercapnia MCA blood flow CVR measures are shown in Fig. 5 panel 251 
b. For the ramp protocol, the MCA blood velocity was sectioned into 14 second averages 252 
corresponding to each CSA image along the ramp protocol. Each of these averaged MCA blood 253 
velocity values were multiplied by the corresponding CSA for the given time point to calculate 254 
blood flow at 14 second increments along the ramp protocol. To keep it consistent with the MCA 255 
blood velocity CVR measures, the PETCO2 slopes from the TCD sessions were used as the 256 
denominator during CVR calculations. The slopes were calculated for each person and the MCA 257 
blood flow CVR was calculated for each individual as:  258 
MCA Blood Flow CVR	=	MCA Blood Flow Slope
PETCO2 Slope
    (3) 259 
Finally, to compare the MCA blood velocity CVR values and the MCA blood flow CVR values 260 
calculated during the steady-state hypercapnia protocol, the percentage change from baseline for 261 
each of the MCA blood velocity or blood flow were calculated (Fig. 5, panel c).  262 
Statistical summary  263 
Inter-rater variability was assessed using Bland-Altman analysis for 45 randomly selected images. 264 
Pearson’s correlation coefficient was used to test the correlation for inter-modality (TCD vs. PC-265 
MRI; Fig. 2) MCA blood velocity measures for both baseline and steady-state hypercapnia states 266 
(P < 0.05 was considered to be statistically significant using a two-tailed test). In addition, linear 267 
slope analysis was conducted to assess changes in PETCO2, MAP, MCA CSA, and MCA blood 268 
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velocity variables during the ramp protocol. A probability level of P<0.05 indicates a non-zero 269 
slope (the linear fits and p-values are labelled on Fig. 3 panels a-e). One-tailed paired t-tests were 270 
conducted to compare variable responses during the steady-state hypercapnia condition versus 271 
baseline (Fig. 4). Finally, to compare the MCA blood velocity CVR values and the MCA blood 272 
flow CVR values calculated during the steady-state hypercapnia protocol, the percentage change 273 
from baseline for each of the MCA blood velocity or blood flow was calculated (Fig. 5).  274 
Results 275 
Our CVR protocols with target PETCO2 are illustrated in Fig. 1. Inter-rater variability for CSA 276 
measures using the Bland-Altman test indicated a bias of 0.15 ± 0.26 mm2 (mean ± S.D.; BKA - 277 
MK) and 95% Limits of Agreement from -0.37 to 0.67 mm2 (45 randomly selected images). Inter-278 
modality (TCD vs PC-MRI) correlation for MCA blood velocity measures indicated a significant 279 
Pearson correlation between baseline and steady-state hypercapnia for each modality (n = 11 280 
participants, 22 pairs; r = 0.69, P < 0.05; Fig. 2). 281 
 
 
Figure 2 – MCA blood velocity measure comparison 
between TCD and PC-MRI. Correlation plot comparing 
MCA blood velocity measured from transcranial Doppler 
(TCD) and phase contrast magnetic resonance imaging 
(PC-MRI). Baseline measures for both TCD and MRI 
sessions and steady-state hypercapnia measure at the ~1-
2 minute mark for PC-MRI and in the last minute of 
steady-state hypercapnia for the TCD session for 22 pairs 
(n=11; r = 0.69, P<0.05). 
 
Slope analysis during the ramp protocol indicated significant slopes (P<0.05; Fig. 3 panels a - d) 282 
for achieved ∆PETCO2 (mmHg) during TCD (Y = 0.033*X – 3.96; R2 = 0.88) and MRI (Y = 283 
0.027*X – 2.54; R2 = 0.77) sessions, with corresponding slopes for ∆MCA blood velocity (cm/s; 284 
Y = 0.13*X – 13.70; R2 = 0.59) and ∆MAP (mmHg; Y = 0.009*X – 0.38; R2 = 0.02). Although 285 
significant, the slope for MAP during the ramp protocol indicated an average <2mmHg increase 286 
throughout the protocol. The slope of the MCA CSA with time did not show a deviation from 0 287 
across the ramp protocol (Fig. 3, panel E; Y = 0.0008*X – 0.057; R2 = 0.006).  288 
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Figure 3 – Measured variables during the ramp and steady-state hypercapnia protocols. Ramp 
protocol (228 seconds; top row) responses and steady-state hypercapnia (180 seconds; bottom row) for 
delta changes in each variable from baseline levels are shown. Panel a: achieved PETCO2 for TCD 
session, panel b: achieved PETCO2 for MRI session, panel c: MCA blood velocity in TCD session, panel 
d: mean arterial pressure (MAP), and panel e: MCA cross-sectional area (CSA). The “PC-MRI” text on 
panel e bottom row indicates the variable time window in which PC-MRI images were acquired and there 
was an interruption in the consistent MCA CSA measurements. A 30 second baseline is shown for the 
steady-state hypercapnia condition (bottom row) and hypercapnia is indicated by SSHC on x-axis with a 
vertical line. Linear regressions (panels a-e top row) are shown for each variable in the ramp protocol 
and a significant (non-zero; α level significance 0.05) slope is indicated by P < 0.05. N = 12 for all 
variables with data presented as mean±S.D. 
 
During the steady-state hypercapnia protocol, PETCO2 increased during steady-state hypercapnia 289 
from baseline with a mean difference of 4.45 mmHg and 95% CI of 4.05 to 4.85 when using TCD 290 
(44.3±3.1 vs. 39.9±2.9 mmHg, respectively; n=12, 𝜂p2=0.98, P<0.05; Fig. 4, panel a) and a mean 291 
difference of 3.75 and 95% CI of  3.29 to 4.20 when using MRI (42.7±4.2 vs. 38.9±4.4 mmHg, 292 
respectively; n=12, 𝜂p2=0.97, P<0.05; Fig. 4, panel b) sessions. Similarly, MCA blood velocity 293 
increased with steady-state hypercapnia from baseline with a mean difference of 18 cm/s and 95% 294 
CI of 13 to 24 cm/s in the TCD trial (104±29 vs. 86±24 cm/s, respectively; n=12, 𝜂p2=0.83, P<0.05; 295 
Fig. 4, panel c) and a mean difference of 22 cm/s and 95% CI of 12 to 33 when using MRI (via 296 
PC-MRI; 79±15 vs. 59±9 cm/s, respectively; n=11, 𝜂p2=0.70, P<0.05; Fig. 4 panel e) sessions, and 297 
MCA CSA increased with a mean difference of 0.31 mm2 and 95% CI of -0.03 to 0.66 mm2 during 298 
the MRI session (5.71±1.03 vs. 5.34±0.97 mm2, respectively; n=12, 𝜂p2=0.27, P<0.05; Fig. 4, 299 
panel f). The mean difference in MAP between the last minute of steady-state hypercapnia and 300 
baseline was 1.35 mmHg with a 95% CI of -0.82 to 3.5 mmHg which is most compatible with a 301 
negligible change (90±8 vs. 89±8 mmHg, respectively; n=12; 𝜂p2=0.14, Fig. 4, panel e). Calculated 302 
MCA blood flows (product of MCA blood velocity and CSA) increased from baseline to steady-303 
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state hypercapnia (267±54 vs. 348±78 ml/min, respectively; P<0.05, one-tailed paired t-test) with 304 
a delta calculated blood flow of 81±30 ml/min. 305 
 
Figure 4 – Baseline (B) and steady-state hypercapnia (SSHC) comparisons. Top row: Baseline (B) 
and steady-state hypercapnia (SSHC) measures (n=12 except for panel d where n=11, mean±S.D.). 
Where statistical significance occurs, p-values are indicated above data (ns = not significant; paired t-
test; α level significance 0.05). Bottom row: Individual data points (n=12 except for panel d where n=11) 
comparing baseline (B) to steady-state hypercapnia (SSHC) responses for the same variable in that 
column as top row. The diagonal line (identity line) indicates where data would fall if there was no 
measurable effect of SSHC from B. Data above the identity line indicates an increase in variable measure 
with SSHC (from baseline; B). 
 306 
The mean difference in MCA blood velocity-based measure of CVR between the ramp and steady-307 
state hypercapnia protocols was 0.18 with 95% CI of -0.59 to 0.96 which is most compatible with 308 
a negligible effect of protocol on MCA blood velocity CVR (3.8±1.7 vs. 4.0±1.6 cm/s/mmHg, 309 
respectively; n=12, two-tailed paired t-test, p=0.62, 𝜂p2=0.02, Fig. 5, panel a). The mean difference 310 
in calculated MCA blood flow-based measure of CVR between the steady-state protocol and ramp 311 
protocol was 5.0 with a 95% CI of 2.8 to 7.2 ml/min/mmHg and was statistically significant 312 
(17.3±5.7 vs. 12.3±4.5 ml/min/mmHg, respectively; n=12, two-tailed t-test, P<0.05, 𝜂p2=0.70, 313 
two-tailed t-test; Fig. 5, panel b). Similarly, when calculated as %change in MCA blood velocity 314 
or MCA blood flow over the ∆PETCO2 during hypercapnia, the mean difference between MCA 315 
blood flow CVR and MCA blood velocity CVR was (6.7±1.6 vs. 4.8±2.0 %/mmHg, respectively; 316 
n = 12, P<0.05, one-tailed t-test). Finally, the %change of MCA blood flow was greater than the 317 
%change of MCA blood velocity during the steady-state condition with a mean difference of 6.9 318 
and 95% CI of -0.37 to 14.10 (29.8±8.2 vs. 21.5±9.6 %, respectively; n=12, P<0.05, one-tailed t-319 
test; Fig. 5, panel c). 320 
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Figure 5 – Middle cerebral artery (MCA) blood velocity and flow reactivity across protocols 
Top row: Calculated MCA blood velocity cerebrovascular reactivity (CVR) was not different 
between ramp and steady-state hypercapnia (SSHC; panel a), while MCA blood flow CVR was 
higher in SSHC compared to the ramp protocol (panel b). The percent change in calculated MCA 
blood flow from baseline was higher than the percent change in MCA blood velocity from 
baseline (panel c) with SSHC. Where statistical significance occurs, p-values are indicated above 
data (ns = not significant; paired t-test; α level significance 0.05). N=12 for all variables with data 
presented as mean±S.D. Bottom row: Individual data points (n=12) comparing ramp to steady-
state hypercapnia (SSHC) responses (panels a-b) for the same variable in that column as top row 
or MCA blood velocity to calculated MCA blood flow (panel c). The diagonal line (identity line) 
indicates where data would fall if there was no measurable effect of protocol on CVR measures 
(panels a-b) or effect of accounting for MCA CSA in flow calculations (compared to using MCAv 
alone as an index of flow) when assessing %change of flow or MCAv during SSHC (panel c). 
Data above the identity line indicates an increase in variable measure with SSHC (compared to 
ramp; panels a-b) or higher %change in flow value for a given %change in MCAv. 
 
Discussion 321 
This is the first study to provide MCA CSA measures across ramp and steady-state hypercapnia 322 
protocols, enabled by the ability to obtain MCA CSA measurements every 14 seconds with 323 
prospective targeting of PETCO2. This approach enabled direct comparisons of the steady- state 324 
versus a ramp protocols to establish valid CVR calculations using only measures of flow velocity. 325 
The noteworthy findings of this study are that: 1) the MCA CSA did not change during the ramp 326 
protocol with delta ~ -3 to +4 mmHg of PETCO2, but did increase with steady-state hypercapnia 327 
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~ +4 mmHg of PETCO2), 2) blood pressure remained stable throughout duration of both ramp and 328 
steady-state protocols, and 3) CVR measures based on MCA blood velocity cerebrovascular 329 
reactivity was not different between ramp and steady-state protocols, but 4) MCA blood flow-330 
based CVR was greater during steady-state compared to the ramp protocol. Taken together, the 331 
ramp protocol seems to result in similar CVR values as those observed in the steady-state protocol, 332 
with the added advantage of having minimal and negligible effects on MCA CSA or MAP in the 333 
face of moderate elevations in PETCO2.  334 
Transcranial Doppler – MCA blood velocity & CVR measures 335 
Often, CVR is characterized by the slope in the linear relationship between MCA blood velocity 336 
and PETCO2 with respect to each variable’s relative change with time. The relationship between 337 
arterial blood velocity and CO2 (16) is sigmoidal and both the range and starting point of PETCO2 338 
affect the arterial blood velocity response to CO2 (17). Regan et al. (7) showed a lower MCA blood 339 
velocity-based CVR during steady-state hypercapnia (∆PETCO2 of 10 mmHg) than during the 340 
ramp hypercapnic protocol (-5 to +10 mmHg PETCO2). However, these ranges of PETCO2 can 341 
elicit systemic hemodynamic effects (6) that can increase blood velocity changes independent of 342 
cerebral vascular bed dilation. The current protocols used a lower dose of change in PETCO2 in 343 
order to avoid the central hemodynamic and non-linear portions of the CVR curve.  344 
MRI – MCA CSA & CVR measures 345 
In the current study, PETCO2 values at the ends of both ramp and steady-state hypercapnia 346 
protocols, and the calculated MCA blood velocity CVR measures, were not different between the 347 
two protocols. Yet, the PETCO2 changes during the ramp protocol did not affect MCA CSA in 348 
same the way that the steady-state hypercapnia protocol did. To quantify transient MCA CSA 349 
measures, we developed an anatomical scan optimized to provide MCA images every 14 seconds. 350 
This enabled imaging of the MCA during the dynamic stimuli such as the ramp protocol or onset 351 
of the steady state protocol, as well as improving temporal sensitivity during the steady-state 352 
model. To our knowledge, our 14 second anatomical scan of MCA CSA provides the highest level 353 
of temporal resolution (i.e., shortest acquisition time) available when compared to existing 354 
assessments of MCA CSA during steady-state hypercapnia protocols. From our current MCA CSA 355 
findings, the MCA dilates under conditions where hypercapnia is elevated and sustained (i.e. 356 
steady-state hypercapnia), rather than with brief exposure to elevated levels of PETCO2 (i.e., end 357 
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of ramp protocol). This observation is supported by previous studies indicating a slow onset to 358 
dilation in either the internal carotid artery (18) or the MCA (2), despite immediate changes in 359 
MCA blood velocity that reflect downstream microvascular dilation to early hypercapnia.  360 
This study supports previous MCA CSA findings in CVR studies that indicate MCA CSA dilates 361 
after ~2 minutes of steady-state hypercapnia using 3T (2) and 7T MRI (4,5). Thus, CVR values 362 
during the steady-state protocol indicated significant error when the MCA cross-sectional area was 363 
not included. Specifically, we found that the %change in MCA blood velocity was lower than the 364 
%change in MCA blood flow by ~7% (mean difference between these two measures). This value 365 
is less than the 18% observed in work by Coverdale et al. (2). We believe the discrepancy in these 366 
mean differences is due to the magnitude of hypercapnia achieved in each study, with ~ +∆4 mmHg 367 
PETCO2 in the current study versus ~ +∆10 mmHg in PETCO2 for the study by Coverdale et al. 368 
As well, there was a 5% increase in MAP in the study by Coverdale et al. (~4 mmHg) which was 369 
greater than the increase in MAP for our study (~2 mmHg for ramp, and ~1 mmHg for steady-370 
state), a difference that may be attributed to the greater magnitude of the hypercapnia stimulus in 371 
the the previous study. While mild variations in MAP are accounted for by autoregulatory 372 
mechanisms such that MCA blood flow is sustained with negligible influence on MCA CSA, 373 
autoregulation mechanisms are impaired during hypercapnia (19). Thus, we anticipate that the 374 
higher the hypercapnic magnitude, the greater the risk that MAP will influence MCA CSA (and/or 375 
blood velocity) augmenting any discrepancies between MCA blood velocity and calculated MCA 376 
blood flow.  377 
This is the first study to use a sequential gas delivery circuit (via the RespirAct™) when assessing 378 
MCA CSA responses during hypercapnia, thereby more closely aligning partial pressure of arterial 379 
and end-tidal CO2 levels (20). Interestingly, we achieved similar MCA blood flow CVR during 380 
steady-state hypercapnia as previous work (2), and our MCA blood velocity CVR for both the 381 
steady-state hypercapnia (2,21) and ramp protocol (7) were in agreement with previous studies. 382 
As recommended by Regan et al. (7), when using a limited range of PETCO2 values during a 383 
hypercapnic protocol, a linear approach to CVR analysis is appropriate.  384 
Everything considered, a CVR measure based solely on TCD-acquired MCA blood velocity 385 
measures during a ramp hypercapnia protocol seems to elicit a similar CVR outcome as the 386 
commonly used steady-state protocol, but without the limitation of potential changes in MCA 387 
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CSA. CVR outcome measures involve calculating MCA blood velocity changes for a given change 388 
in PETCO2. Similarly, our study illustrates that even modest values of change in PETCO2 achieve 389 
a comparable value of CVR at higher hypercapnic doses. 390 
Methodological Considerations 391 
Our overall target range for manipulating PETCO2 during the cerebrovascular reactivity was 392 
between the -∆5 to +∆5 from baseline PETCO2 (10). While our findings support a lack of MCA 393 
CSA changes during ramp protocols of -∆3 to +∆4 mmHg in PETCO2, we cannot make conclusive 394 
remarks on MCA CSA changes during a ramp protocol of ±∆5mmHg in PETCO2. However, as 395 
mentioned above, our values of ∆PETCO2 fell within our target ±∆5mmHg from baseline PETCO2 396 
range, the CVR measures are consistent with previous studies where higher levels of PETCO2 397 
were used, and we found negligible increases in MAP. Therefore, the modest level of PETCO2 398 
achieved here appear to have achieved the major objectives. The ramp protocol designed for the 399 
current study also achieved an optimal balance between stimulus and central hemodynamics. We 400 
acknowledge however, that we did not account for the impact of the ~2 mmHg rise in MAP during 401 
the ramp protocol, which we expect to be negligible in impacting MCA CSA. 402 
Although we were unable to measure continuous blood pressure and MCA blood velocity during 403 
the MRI trial, we measured blood velocity data during the MRI session via the PC-MRI sequence. 404 
Testing of the TCD and MRI segments of the study were collected consecutively within a 2-hour 405 
window with the order of tests varied across participants. The absolute values for MCA blood 406 
velocities measured by PC-MRI were lower than our TCD measures, although we suspect this had 407 
to do with our pre-set Venc value choice of 100 cm/s which may have cut off some of the higher 408 
velocities. Our rationale for not choosing a higher Venc than 100 cm/s was the possibility of cutting 409 
off lower velocity values during baseline. Regardless, the increase in MCA blood velocity during 410 
hypercapnia (from baseline) were in agreement between the two techniques (TCD: ~∆18 cm/s and 411 
PC-MRI: ~∆20 cm/s). Thus, we assume that the blood pressure responses during the TCD and 412 
MRI sessions were similar as well.  413 
Finally, the current results are delimited to young healthy adults Thus, additional studies are 414 
needed to understand the effects of age, a group that demonstrates greater MAP responses to 415 
hypercapnia and variable responses in CSA changes (9), or other differentiating conditions. 416 
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Further, our study was conducted in the supine position, which is less replicable for CVR studies 417 
than the seated position (22) and may explain some of the disparity of blood velocity measures for 418 
some individuals between the two protocols: the supine posture is necessary for MRI studies. 419 
Additional studies are required to address the impact of CSA changes and protocol model on 420 
posture-dependent intra-subject variability so that reliable CVR protocols can be used to make 421 
inferences on vascular health (e.g., inferred vascular dysfunction with reduced CVR). The current 422 
data suggest that the ramp protocol might be useful in reducing inter-study variability.  423 
Conclusions 424 
A constant CSA during experimental vasoreactive challenges is essential to the reliability of TCD-425 
acquired blood velocity as a correlative index of blood flow changes. In this study, we showed 426 
data that were most compatible with negligible change in MCA CSA from baseline during a graded 427 
ramp hypercapnic protocol (± ~∆4 mmHg from baseline PETCO2). Similar to our previous work, 428 
the MCA data align best with an interpretation of MCA dilation during a prolonged (3-minutes) 429 
~∆4 mmHg in baseline PETCO2 period of hypercapnia, and confirmed the expected error in 430 
%change of MCA blood velocity as an index of blood flow and in the calculated CVR when a 431 
change in CSA is not considered (2). Combined, these data suggest that during transient changes 432 
in PETCO2, as in the ramp protocol, the constant segment of the sigmoid may describe MCA CSA 433 
changes with PETCO2, and any changes in blood velocity can reflect CBF. In summary, the ramp 434 
protocol with ± ~∆4 mmHg from baseline PETCO2 appears to provide expected measures of CVR 435 
where blood velocity should reflect blood flow patterns of change.  436 
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